1. 1575A 28-day high-dose safety and pharmacokinetics study of raltegravir in healthy subjects. (December 2014) Authors: Krishna, Rajesh; Rizk, Matthew; Schulz, Valerie; Bruggencate-Broeders, Jolanda; Liu, Ran; Larson, Patrick; Abou-Farha, Khalid Journal: Open forum infectious diseases Issue: Volume 1(2014)Supplement 1 Page Start: S419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment. Issue 2 (26th October 2020) Authors: Tatosian, Daniel A.; Yee, Ka Lai; Zhang, Zufei; Mostoller, Kate; Paul, Erina; Sutradhar, Santosh; Larson, Patrick; Chhibber, Aparna; Wen, Jianzhong; Wang, Ya‐Juan; Lassman, Michael; Latham, Andrew H.; Pang, Jianmei; Crumley, Tami; Gillespie, Anne; Marricco, Nadia Cardillo; Marenco, Ted; Murphy, M... Journal: Clinical pharmacology & therapeutics Issue: Volume 109:Issue 2(2021) Page Start: 403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment. Issue 2 (26th October 2020) Authors: Tatosian, Daniel A.; Yee, Ka Lai; Zhang, Zufei; Mostoller, Kate; Paul, Erina; Sutradhar, Santosh; Larson, Patrick; Chhibber, Aparna; Wen, Jianzhong; Wang, Ya‐Juan; Lassman, Michael; Latham, Andrew H.; Pang, Jianmei; Crumley, Tami; Gillespie, Anne; Marricco, Nadia Cardillo; Marenco, Ted; Murphy, M... Journal: Clinical pharmacology & therapeutics Issue: Volume 109:Issue 2(2021) Page Start: 403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A Phase 1 Trial to Evaluate the Relationship Between Fluoride Intake and Urinary Fluoride Excretion in Healthy Participants. (12th November 2021) Authors: Gillespie, Gillian; Jackson Rudd, Deanne; Zhang, Saijuan; Schaeffer, Andrea; Tomek, Charles; Larson, Patrick; Stoch, S. Aubrey; Iwamoto, Marian Journal: Journal of clinical pharmacology Issue: Volume 62:Number 2(2022) Page Start: 190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose. (4th November 2016) Authors: Krishna, Rajesh; East, Lilly; Larson, Patrick; Valiathan, Chandni; Deschamps, Kathleen; Luk, Julie Ann; Bethel‐Brown, Crystal; Manthos, Helen; Brejda, John; Gartner, Michael Journal: Biopharmaceutics & drug disposition Issue: Volume 37:Number 9(2016:Dec.) Page Start: 533 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir. (14th November 2016) Authors: Krishna, Rajesh; East, Lilly; Larson, Patrick; Siringhaus, Tara; Herpok, Lisa; Bethel‐Brown, Crystal; Manthos, Helen; Brejda, John; Gartner, Michael Journal: Biopharmaceutics & drug disposition Issue: Volume 37:Number 9(2016:Dec.) Page Start: 542 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. (27th September 2016) Authors: Krishna, Rajesh; East, Lilly; Larson, Patrick; Valiathan, Chandni; Butterfield, Kristin; Teng, Yang; Hernandez-Illas, Martha Journal: Journal of pharmacy and pharmacology Issue: Volume 68:Number 11(2016:Nov.) Page Start: 1359 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Effect of metal‐cation antacids on the pharmacokinetics of 1200 mg raltegravir. (27th September 2016) Authors: Krishna, Rajesh; East, Lilly; Larson, Patrick; Valiathan, Chandni; Butterfield, Kristin; Teng, Yang; Hernandez‐Illas, Martha Journal: Journal of pharmacy and pharmacology Issue: Volume 68:Number 11(2016:Nov.) Page Start: 1359 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor. (12th November 2021) Authors: Gillespie, Gillian; Jackson Rudd, Deanne; Zhang, Saijuan; Schaeffer, Andrea; Tomek, Charles; Larson, Patrick; Stoch, S. Aubrey; Iwamoto, Marian Journal: Journal of clinical pharmacology Issue: Volume 62:Number 2(2022) Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. (6th June 2014) Authors: Lauring, Brett; Li, Xiujiang (Susie); Liu, Yang; Corr, Christy; Lazarus, Nicole; Cote, Josee; Larson, Patrick; Levonas, Amy O. Johnson; Lasseter, Kenneth C.; Preston, Richard A.; Smith, William B.; Lai, Eseng; Wagner, John A. Journal: Journal of clinical pharmacology Issue: Volume 54:Number 11(2014:Nov.) Page Start: 1247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗